Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04526106
Title	REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Relay Therapeutics, Inc.
Indications	Advanced Solid Tumor
Therapies	Lirafugratinib
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| AUS